Academic literature on the topic '307.76/8'

Investigations were carried out to identify the source of resistance in 67 bottle gourd genotypes for gummy stem blight, powdery mildew and cucumber green mottle mosaic virus (CGMMV) diseases, under natural field epiphytotic conditions. The genotypes BG-95 (105.13), BG-114-1 (131.04), BG-114-3 (208.81) and BG-77-6-1 (221.80) were resistant for gummy stem blight with low AUDPC values, while, BG-125-5 (232.22), BG-6-3 found (250.00), BG-125-4 (307.78), BG-8-1 (308.89), BG-125-2 (311.11) and BG-124-2 (423.33) resistant with low AUDPC values for powdery mildew. Further, the two genotypes such as IIHR-19 and BG- 131 showed field level resistance against CGMMV. The selected genotypes based on field evaluation were subjected for artificial screening under glass house conditions. The genotypes, recorded consistent resistant reactions were BG-114-3, BG-77-6-1 and BG-95 for gummy stem blight disease and BG-6-3, BG-8-1, BG-125-4 and BG-125-2 for powdery mildew. The stable and durable source of resistance identified for gummy stem blight and powdery mildew in bottle gourd genotypes will hasten the process of developing resistance varieties in bottle gourd.

Abstract Human bone is a composite material of hydroxyapatite (HA) and collagen. HA (Ca10(PO4)6(OH)2) is a biomaterial with the calcium to phosphorus ratio being similar to the natural bone composition. In this study, composite materials were prepared by using poly(lactic acid) (PLA) as a polymer matrix, maleic anhydride (MAH) as a compatibilizer, and natural HA extracted from cow bone (BHA) as a suitable mechanical support filler with positive surface properties. Composites with varying HA (10-30 wt. %), PLA, and with or without MAH (0.5–8 wt. %) were prepared by a thermal decomposition method at 900 ℃. In comparison to commercial HA (CHA), the effect of the PLA and MAH contribution on morphological, thermal, and mechanical properties of BHA were analyzed by X-ray diffraction (XRD), Fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), scanning electron microscopy (SEM) and tensile strength measurements. As per the results, the HA30/PLA/4MAH composite with 30 wt. % HA, 66 wt. % PLA and 4 wt. % MAH offer the maximum mean tensile strength of 307.71 MPa. The overall results confirm the contribution of MAH compatibilizer in HA/PLA/MAH composite materials for bone tissue engineering from a mechanical point of view.

Abstract Background IgA is the predominant antibody class secreted by intestinal immune cells. However, the level of plasma IgA in Inflammatory Bowel Disease (IBD) patients under medical treatment remains unknown. Therefore, our study aimed to investigate the relationship between plasma IgA concentration in IBD patients under biological therapy. Aims To assess the correlation between plasma IgA level in IBD patients under biological therapy. Methods We collected data from outpatient clinics at our hospital, including 12 IBD patients, comprising 4 patients with Crohn's disease (CD) and 8 patients with Ulcerative Colitis (UC). Data was collected between 2020 and 2023. We measured plasma IgA concentrations both before initiating biologic therapy and at the 14th week of biological treatment (4 under Adalimumab and 8 under Vedolizumab). Additionally, we compared baseline plasma IgA levels between 24 IBD patients (7 CD and 17 UC) and 24 healthy individuals. Student T test was used for statistical analyze. Results The average baseline plasma IgA level was significantly higher in IBD patients (2134±187.2 ug/ml, mean ± standard error) when compared to healthy individuals (1346± 114.8 ug/ml, p=0.0008). In the view of CD and UC, the baseline plasma IgA level was 2179±439.4 ug/ml and 2116±203.1 ug/ml, respectively. Baseline plasma IgA level also showed statistical significantly higher in CD and UC compared to healthy individuals (p=0.0063, p=0.0005, respectively), and without difference between UC and CD patients (p=0.8824) (Figure 1A). Furthermore, we investigated the impact of biological therapy on plasma IgA levels in IBD patients, finding a significant decrease in plasma IgA levels after biological therapy (2182±254.7 ug/ml to 1824±135.5 ug/ml, p=0.0181). Similar trend was noted in UC patients under biological therapy with borderline statistical significant (2141± 307.7ug/ml to1809±173.3ug/ml, p=0.0561), but not found in CD patients (2265±518.3 ug/ml to 1855±247.5 ug/ml, p= 0.1333)(Figure 1B). Conclusions We found that baseline plasma IgA level was higher in IBD patients compared to healthy individuals. Besides, plasma IgA level decreased after biological therapy in IBD patients, especially in UC patients. These findings suggest that plasma IgA level may be a potential biomarker for IBD patients. Funding Agencies None

Abstract. Arrays of GPS Ionospheric Scintillation and TEC Monitors (GISTMs) are used in a comparative scintillation study focusing on quasi-conjugate pairs of GPS receivers in the Arctic and Antarctic. Intense GPS phase scintillation and rapid variations in ionospheric total electron content (TEC) that can result in cycle slips were observed at high latitudes with dual-frequency GPS receivers during the first significant geomagnetic storm of solar cycle 24 on 5–7 April 2010. The impact of a bipolar magnetic cloud of north-south (NS) type embedded in high speed solar wind from a coronal hole caused a geomagnetic storm with maximum 3-hourly Kp = 8- and hourly ring current Dst = −73 nT. The interhemispheric comparison of phase scintillation reveals similarities but also asymmetries of the ionospheric response in the northern and southern auroral zones, cusps and polar caps. In the nightside auroral oval and in the cusp/cleft sectors the phase scintillation was observed in both hemispheres at about the same times and was correlated with geomagnetic activity. The scintillation level was very similar in approximately conjugate locations in Qiqiktarjuaq (75.4° N; 23.4° E CGM lat. and lon.) and South Pole (74.1° S; 18.9° E), in Longyearbyen (75.3° N; 111.2° E) and Zhongshan (74.7° S; 96.7° E), while it was significantly higher in Cambridge Bay (77.0° N; 310.1° E) than at Mario Zucchelli (80.0° S; 307.7° E). In the polar cap, when the interplanetary magnetic field (IMF) was strongly northward, the ionization due to energetic particle precipitation was a likely cause of scintillation that was stronger at Concordia (88.8° S; 54.4° E) in the dark ionosphere than in the sunlit ionosphere over Eureka (88.1° N; 333.4° E), due to a difference in ionospheric conductivity. When the IMF tilted southward, weak or no significant scintillation was detected in the northern polar cap, while in the southern polar cap rapidly varying TEC and strong phase scintillation persisted for many hours. This interhemispheric asymmetry is explained by the difference in the location of solar terminator relative to the cusps in the Northern and Southern Hemisphere. Solar terminator was in the immediate proximity of the cusp in the Southern Hemisphere where sunlit ionospheric plasma was readily convected into the central polar cap and a long series of patches was observed. In contrast, solar terminator was far poleward of the northern cusp thus reducing the entry of sunlit plasma and formation of dense patches. This is consistent with the observed and modeled seasonal variation in occurrence of polar cap patches. The GPS scintillation and TEC data analysis is supported by data from ground-based networks of magnetometers, riometers, ionosondes, HF radars and all-sky imagers, as well as particle flux measurements by DMSP satellites.

Abstract We previously demonstrated that children with mature B-NHL with local, intermediate and advanced disease have a 99%, 92%, and 80% 5 yr EFS, respectively, with FAB multiagent chemotherapy (Gerrard/Cairo/Patte et al, Br J Haem, 2008, Patte/Gerrard/Cairo et al, Blood, 2007, and Cairo/Gerrard/Patte et al, Blood, 2007). Despite these outstanding clinical results, the incidence of grade III/IV mucositis and infection ranges from 40–70% resulting in prolonged hospitalization and increased costs. Furthermore, subsets of pts have a poorer prognosis; poor COP response, PBML, combined BM/CNS, high tumor burden by LDH 2 upper limits, and/or complex cytogenetics. We previously demonstrated CD20, the receptor to the chimeric antibody rituximab, is expressed in over 98% of all children with mature B-NHL (Perkins/Cairo et al, Clin Adv Hem, 2003). In adults (30–60 yrs) and elderly adults (□ 60 yrs) with DLBCL, the addition of rituximab to CHOP or CHOP like chemotherapy has significantly increased the EFS and OS (Pfreundschüh et al, Lancet Oncology, 2006 and Coiffier et al, NEJM, 2002, respectively). We therefore hypothesized that the addition of rituximab (anti-CD20 antibody) to the FAB chemotherapy backbone in children and adolescents with newly diagnosed intermediate risk (restricted to Stage III/IV) mature B-NHL would be safe and well tolerated and result in 90% 3 yr EFS. We now report the results of 48 pts with stage III/IV (<25% blasts in BM and no CNS) enrolled on COG ANHL01P1. Therapy consisted of FAB Group B4 therapy (adria 1 hr infusion) as we have previously described (Patte/Cairo et al, Blood, 2007) with the addition of rasburicase (0.2 mg/kg/dose), generously supplied by Sanofi-Aventis, during the COP reduction and rituximab 375 mg/m2/dose, generously supplied by Genentech, day -2 and ay 0 in COPADM2 and day 0 in CYM 1 + 2 (4 doses, subpilot) and day -2 and day 0 in COPADM 1 + 2 and day 0 in CYM 1 + 2 (six doses, pilot), respectively. Rituximab levels were measured at baseline, 30–60 minutes after Day -2 and Day 0 in COPADM 1 (pilot) + 2 (subpilot) and 1, 3, and 6 months after the last dose of rituximab and measured by ELISA with a purified polyclonal goat anti-rituximab antibody as the capture reagent and goat antibody to mouse IgG-conjugated to horseradish peroxidase as the detection reagent (detection limit of 0.5 mcg/mL). Toxicity was measured according to the NCI CTCAE 3.0 and EFS and OS were calculated by the KM method. Median age 11 (1–23 yrs), M/F (4:1), Burkitt (59%), DLBCL (24%), PMBL (5%), 11% NOS. LDH 2 time upper institutional limits (45%). The addition of rituximab was safe and well tolerated with 274 infusions and there were no SAEs probably or definitely attributed to rituximab. The incidence of grade III/IV mucositis during COPADM 1 + 2 was 14 and 11%, respectively, compared to 43 and 31% in FABLMB96. Similarly, the incidence of grade III/IV neutropenia/infection during the same two courses was 47% and 29%, respectively, compared to grade IV infection, 49 and 25% in FABLMB 96. The incidence of TLS was only 2.5% during COP-rasburicase reduction. Probability of 1 yr EFS and OS was 96% (95% CI: 88–100%) and 100%, respectively compared to 86% EFS for Stage III/IV intermediate risk pts in FABLMB 96 study. The peak rituximab level 30–60 minutes after the first infusion on day -2, day 0 in COPADM 1 + 2 was 220.4±10.5, 307.7±377.6, 267.3±66.0, and 402.1±38.6 mcg/mL, respectively. The trough levels prior to the second rituximab dose in COPADM 1 + 2 was 128.9±16.9 and 208.5±15.3 mcg/mL, respectively. The levels 1, 3 and 6 months post the last dose of rituximab was 75.0±14.7, 13.0±3.3 and 1.1±0.15 mcg/mL, respectively. There was no significant difference in rituximab levels in BL vs. other mature B-NHL and age < 8 vs 8 yrs. In summary, the addition of rasburicase to FAB COP reduction and rituximab to FAB COPADM 1 + 2 and CYM 1+2 is well tolerated. Rituximab levels are comparable to levels in adults, and in the serum up to 3 months past the last dose. The addition of rituximab to FAB therapy is associated with a superior EFS and OS as compared to similar historical groups of patients and histology treated with FAB chemotherapy alone. Future randomized studies will be required to determine if the addition of rituximab to the FAB chemotherapy backbone in children with intermediate and advanced mature B-NHL will significantly increase EFS/OS and/or facilitate the reduction of intensity of cytotoxic chemotherapy without a diminution in long-term EFS.

Background and Objective: Inflammation was one of the most important pathophysiological processes during myocardial ischemia. However, it is still poorly understood about the possibilities of these pro- or anti-inflammation factors be used as prognostic parameters for subsequent attenuation of heart functions. Methods and Results: Chinese experimental mini swines (25±4 kg) were instrumented with a size-matched Ameroid constrictor on the left anterior descending branch (LAD) under general anesthesia in sterile conditions (N=15). And a sham group (N=6) was included. 4 weeks after thoracotomy, more than 90% occlusion of the LAD was proved by coronary angiography. Early stage of ischemia was found by echocardiography which showed focal ischemia in the anterior wall of left ventricular (from apex to papillary muscle level) and unchanged ejection fraction. Meanwhile, Enzyme-linked immunosorbent assay of serum showed that IL-8 (86.83 ±10.96 vs. 130.3 ±10.94-pg/ml, P =0.0322) and IL-10 (0.9619 ±0.1421 vs. 1.660 ±0.1607-pg/ml, P =0.0111) were dramatically decreased compared to sham group, while no significant changes were found in IL-1 (0.3075 ±0.03558 vs. 0.3045 ±0.057371 -ng/ml, P = 0.9643), IL-6 (307.7 ±27.81 vs. 315.8 ±23.07-pg/ml, P =0.8637), high sensitivity C reactive protein (hsCRP) (12.94 ±1.324 vs. 9.943 ±1.442-ng/ml, P =0.2087) and TNF-a(1.769 ±0.1467 vs. 1.260 ±0.3209-ng/ml, P =0.1121). Furthermore, 8 weeks after thoracotomy, ejection fraction(EF) of myocardial ischemia animals were dramatically attenuated (44.69 ±4.494 vs. 60.60 ±3.420-%, P =0.0428). Subsequent EF (8 weeks postoperation) showed a good linear regression with the IL-10 and hsCRP concentration in the early stage of myocardial ischemia (4 weeks postoperation) (EF= 0.525+ 0.132* IL-10- 0.015* hsCRP, P =0.001) when stepwise regression was performed with all inflammation related factors above as dependent variables. Conclusion: These results demonstrate that lower IL-10 and higher hsCRP in serum may be predictors for the attenuation of heart function caused by myocardial ischemia. Further Clinical trials may help to prove the efficiency of these novel insights of prognosis for ischemia heart diseases.